MEDICINE DETAILS
Afinitor
Active ingredient: Everolimus
Neutral reference profile for an independent medicine-access consultancy enquiry about Afinitor (Everolimus). No medicine is offered for sale.
LEGACY INFORMATION PAGE
This record is retained for information continuity.
This medicine is not currently in the live enquiry directory. You can review the identity and catalogue details below, but an enquiry cannot be created from this page.
Return to the live directory→Retaining this page does not imply stock, access or a medicine sale.
ABOUT THIS MEDICINE
What is Afinitor used for?
Afinitor (everolimus) is an mTOR inhibitor indicated to treat:
- Hormone receptor-positive, HER2-negative advanced breast cancer that has started to spread, in postmenopausal women who have already received certain other medicines for their cancer, in combination with exemestane.
- Advanced renal cell carcinoma (a kidney cancer) when certain other medicines have not worked.
- Advanced pancreatic neuroendocrine tumours (NET) that have progressed and cannot be treated with surgery.
- Advanced gastrointestinal NET that has progressed and cannot be treated with surgery.
- Advanced lung NET that has progressed and cannot be treated with surgery.
- Renal (kidney) angiomyolipoma with a genetic condition called tuberous sclerosis complex (TSC), when their kidney tumor does not require immediate surgery.
- Subependymal giant cell astrocytoma (SEGA; a type of brain tumor) when the tumor cannot be completely removed by surgery.
- Adults and children 2 years of age with TSC, as an added treatment to other antiepileptic medicines.
It is available in tablet form, each containing either 2.5mg, 5mg, 7.5mg, or 10mg of everolimus.
This information is general and is not medical advice. Talk to your doctor or pharmacist about any treatment decision.
RECORDED PRODUCT PROFILE
Afinitor identity, dosage form and pack information.
The details below are assembled from current catalogue records. They must still be checked against the prescription, medicine box and an official regulatory record.
Recorded strength and pack options
Each row is shown only to help identify the product; it is not stock confirmation or a sale offer.
-
2.5 mg · 30 tablets Catalogue organisation: NOVARTIS Pharma GmbH
-
5 mg tablets · 30 tablets Catalogue organisation: Abacus Medicine A/S
-
10 mg tablets · 30 tablets Catalogue organisation: Abacus Medicine A/S
OFFICIAL SOURCES
Check the Afinitor record at an official source.
Search for “Afinitor” or “Everolimus”. Finding a product in one source does not by itself confirm stock, authorisation in a particular country or suitability for a patient.
OFFICIAL EXTERNAL SOURCE
European Medicines Agency (EMA)
Search medicines evaluated by EMA by brand name or active substance. EMA also links to national registers for nationally authorised products.
↗ OFFICIAL EXTERNAL SOURCE Drugs@FDASearch FDA-approved human drug records by brand name or active ingredient, including current labelling where available.
↗SERVICE BOUNDARY
Information checking and independent enquiry support for Afinitor.
OrphanDrug helps organise the product identity and recorded strength and pack details for an enquiry. It does not sell, take payment for, prescribe, import, dispense or deliver medicines.
Clinical decision: Only a qualified healthcare professional who has assessed the patient can decide whether a product, form or dose is appropriate.
CLEAR ANSWERS
Frequently asked questions about Afinitor
01What is Afinitor?＋
This directory record associates the brand name Afinitor with the active ingredient Everolimus. The brand and ingredient are shown for product identification only, not as treatment or dosing advice.
02Which Afinitor strengths and packs are recorded?＋
The catalogue currently shows: 2.5 mg · 30 tablets; 5 mg tablets · 30 tablets; 10 mg tablets · 30 tablets. Check the complete strength, dosage form and pack description against the prescription and medicine box.
03Who manufactures Afinitor?＋
Catalogue records currently name: NOVARTIS Pharma GmbH, Abacus Medicine A/S. This field may identify a manufacturer, marketing-authorisation holder, marketing company or supplier; confirm the exact role on the pack leaflet and official regulatory record.
04Do the listed options confirm stock or access?＋
No. A catalogue record does not confirm current stock, authorisation in a particular country, clinical suitability, import permission or access.
05What affects a possible estimated medicine cost for Afinitor?＋
A possible cost depends on the exact strength, dosage form, pack, quantity, destination and regulatory jurisdiction. Any amount provided after an enquiry is an indicative medicine-cost estimate only, not a selling price for Afinitor, payment request, stock guarantee or binding offer.
06Can I buy Afinitor from this website?＋
No. This website does not sell, take payment for, prescribe, import, dispense or deliver medicines. The form creates an independent consultancy enquiry only.